← Back to Search

Antibiotic

GSK3882347 for Urinary Tract Infection (UTI)

Phase 1
Waitlist Available
Research Sponsored by GlaxoSmithKline
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 2 days
Treatment Varies
Follow Up day 10 to day 13

Summary

This trial tests a new medication, GSK3882347, to treat urinary tract infections in adult women. The study will see if the medication can effectively clear the infection and check for any side effects. Participants will take the medication for a short period, and researchers will compare it to an existing treatment to ensure accurate results.

Eligible Conditions
  • Urinary Tract Infection (UTI)

Timeline

Screening ~ 2 days
Treatment ~ Varies
Follow Up ~day 10 to day 13
This trial's timeline: 2 days for screening, Varies for treatment, and day 10 to day 13 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Numbers of participants with microbiological response (responder/non-responder of GSK3882347) at the test of cure (TOC) visit
Secondary study objectives
Number of participants with adverse events (AEs) and serious adverse events (SAEs)
Number of participants with clinically significant change from baseline in 12- lead Electrocardiogram (ECG) findings
Number of participants with clinically significant change from baseline in clinical chemistry
+5 more

Side effects data

From 2021 Phase 1 trial • 61 Patients • NCT04488770
17%
Head injury
17%
Presyncope
17%
Headache
100%
80%
60%
40%
20%
0%
Study treatment Arm
Part 1: Single Dose Placebo
Part 1: Single Dose GSK3882347 15 mg
Part 1: Single Dose GSK3882347 50 mg
Part 1: Single Dose GSK3882347 500 mg
Part 1: Single Dose GSK3882347 900 mg
Part 2: Repeat Dose Placebo
Part 2: Repeat Dose GSK3882347 50 mg
Part 2: Repeat Dose GSK3882347 150 mg
Part 1: Single Dose GSK3882347 150 mg
Part 2: Repeat Dose GSK3882347 900 mg
Part 1: Single Dose GSK3882347 250 mg
Part 1: Single Dose GSK3882347 250 mg Fed
Part 2: Repeat Dose GSK3882347 500 mg

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: GSK3882347 + PlaceboExperimental Treatment2 Interventions
Participants will be administered GSK3882347 plus placebo.
Group II: Nitrofurantoin+ PlaceboActive Control2 Interventions
Participants will be administered nitrofurantoin plus placebo.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
GSK3882347
2020
Completed Phase 1
~90
Placebo
1995
Completed Phase 3
~2670

Find a Location

Logistics

Travel, including flights, are covered

Your expenses for travel tickets for this trial will be reimbursed.

Other reimbursement is provided

Other forms of reimbursement are provided for this trial.

Who is running the clinical trial?

GlaxoSmithKlineLead Sponsor
4,805 Previous Clinical Trials
8,379,769 Total Patients Enrolled
1 Trials studying Urinary Tract Infection
2,648 Patients Enrolled for Urinary Tract Infection
GSK Clinical TrialsStudy DirectorGlaxoSmithKline
3,604 Previous Clinical Trials
6,144,809 Total Patients Enrolled
~23 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top